Company news
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) news
Every Aurinia Pharmaceuticals Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business...
August 6, 2026
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in...
July 6, 2026
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
June 4, 2026
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
June 3, 2026
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
May 19, 2026
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
May 7, 2026
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
March 30, 2026
Aurinia Announces Management Transition
March 23, 2026
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent B...
February 26, 2026
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent ...
February 19, 2026
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
December 16, 2025
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Bu...
November 4, 2025
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent B...
November 3, 2025
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of...
October 15, 2025
Aurinia Responds to Now Retracted LinkedIn Post
September 29, 2025
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
July 31, 2025
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
July 22, 2025
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
June 30, 2025
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
June 29, 2025
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
May 22, 2025
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
May 12, 2025
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
May 5, 2025
Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
April 30, 2025
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
April 30, 2025
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
April 29, 2025
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
April 29, 2025
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent C...
February 27, 2025
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
February 20, 2025
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
November 18, 2024
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® i...
November 15, 2024
Aurinia to Participate in Jefferies London Healthcare Conference
November 14, 2024
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring t...
November 7, 2024
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
November 7, 2024
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
October 30, 2024
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of N...
October 11, 2024
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
September 24, 2024
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
September 13, 2024
Aurinia Announces Board Restructuring
September 12, 2024
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
September 5, 2024
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
August 1, 2024
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 2, 2024
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheuma...
June 5, 2024
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 4, 2024
Aurinia Provides Update on Proxy Statement
June 3, 2024
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Me...
May 14, 2024
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East...
May 9, 2024